Comparative Pharmacology
Head-to-head clinical analysis: DISPERMOX versus PIPERACILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISPERMOX versus PIPERACILLIN.
DISPERMOX vs PIPERACILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Adults: 1 g (as amoxicillin 875 mg + clavulanate 125 mg) orally every 12 hours for 7-10 days.
3.375 g IV every 6 hours (piperacillin-tazobactam); for piperacillin alone, 3 g IV every 6 hours.
None Documented
None Documented
Terminal elimination half-life 1.5 hours; prolonged in renal impairment.
Clinical Note
moderatePiperacillin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Piperacillin."
Clinical Note
moderatePiperacillin + Mycophenolic acid
"The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Piperacillin resulting in a loss in efficacy."
Clinical Note
moderatePiperacillin + Plicamycin
"The serum concentration of Plicamycin can be decreased when it is combined with Piperacillin."
Clinical Note
moderate0.6-1.2 hours in adults with normal renal function; prolonged to 2-6 hours in renal impairment (CrCl <20 mL/min); requires dose adjustment in renal failure
Renal excretion 80% as unchanged drug, biliary/fecal 10%.
Renal: approximately 70-90% unchanged via glomerular filtration and tubular secretion; biliary: 10-20% excreted unchanged in bile; fecal: minor (<5%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic
Piperacillin + Valrubicin
"The serum concentration of Valrubicin can be decreased when it is combined with Piperacillin."